Overview
Bright Minds Biosciences designs next-generation serotonergic compounds targeting specific 5-HT receptor subtypes to treat epilepsy, PTSD, and addiction with reduced side effects. Their platform leverages computational drug design to create highly selective psychedelic-inspired molecules.
More in Mental Health Tech
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
💙 Mental Health Tech
Location
Vancouver, Canada
Funding
Public · NASDAQ: DRUG
Website
brightmindsbiosciences.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →